425+ Articles, Abstracts, and Posters
Providing Full Support For All of Our Products
Biopreserved in Home-Brew Media
Biopreserved in HypoThermosol
Ask the Scientists
Help is Available To Answer All of Your Biopreservation Questions
BioLife Solutions has been pioneering Biopreservation Best Practices for Cell Therapy and Regenerative Medicine, Drug Discovery, and Biobanking for over 20 years. A key component of our customer success has been our unique and collaborative relationship with industry and the research community; especially supporting the optimization of methods and integration with Good Manufacturing Practice (GMP). Aby J. Mathew, Ph.D. and our team of Ph.D. scientists have enabled biopreservation standardization and optimization for a diverse spectrum of customer applications, and are available to answer any questions you may have. For example:
- Which variant of CryoStor is best for T cells?
- Can HypoThermosol be infused/injected into humans?
- What post-thaw assays are best for cell recovery?
In addition, scientific collaboration and in-depth consultative services are available for our research and clinical partners. With the experience of 200+ customer Regenerative Medicine applications, 425+ scientific citations, and 500+ customers, it is our mission to support Biopreservation Best Practices.
Please fill out the below form to get started.
Bio: Aby J. Mathew, PhD – Executive Vice President & Chief Scientific Officer, BioLife Solutions Inc.
Dr. Mathew was part of the founding team of BioLife Solutions, Inc., and is a co-developer of BioLife’s biopreservation media solutions. He is a co-inventor on multiple issued and pending patents related to methods, devices, and formulations for the preservation of cells, tissues, and organs. He holds a Ph.D. in Biological Sciences within the Biochemistry, Cell and Molecular Biology Program from Binghamton University and a B.S. in Microbiology from Cornell University. Dr. Mathew has been researching low temperature biopreservation since 1994, and his studies contributed to the development of BioLife’s current commercial HypoThermosol® and CryoStor® product platforms and intellectual property foundation. Dr. Mathew was part of the scientific team that linked cell death via apoptosis (programmed cell death) to exposure to hypothermic and/or freezing temperatures. These discoveries were integral to the development of BioLife’s intracellular-like biopreservation media, and also contributed to improvements in cryosurgical ablation of cancer. Dr. Mathew was BioLife’s first Director of Manufacturing, established BioLife’s initial Quality system, and has been Executive Vice President & Chief Scientific Officer since December 2019. From February 2011 through November 2019, Dr. Mathew served as Senior Vice President & Chief Technology Officer. From January 2007 through February 2011, Dr. Mathew served as Senior Scientist, Director of Strategic Relations, and Senior Director of Strategic Relations. From June 2003 through January 2007, Dr. Mathew served as Director of Manufacturing. From September 2000 through June 2003, Dr. Mathew served as Clinical Accounts Manager and Director of Hypothermic Preservation for Cryomedical Sciences/BioLife Solutions. Dr. Mathew is currently active in, or previously a member of, AABB (formerly the American Association of Blood Banks), BEST (the Biomedical Excellence for Safer Transfusion collaborative), the International Society for Cell and Gene Therapy (ISCT), the Alliance for Regenerative Medicine (ARM), Tissue Engineering & Regenerative Medicine International Society (TERMIS), Society for Cryobiology, International Society for Biological and Environmental Repositories (ISBER), American Society for Cell Biology, and the Society for In Vitro Biology. Dr. Mathew is a member of: the Board of Directors, and Advisory Panel, of the Parent’s Guide to Cord Blood Foundation, the Scientific Advisory Board of HemaCare Corporation, the founding Board of Directors of the Cord Blood Association, the NIST-AMTech National Cell Manufacturing Consortium, the California Institute for Regenerative Medicine (CIRM) Clinical Advisory Panel, the Business Advisory Board of RoosterBio Inc., and the Scientific Advisory Board of SAVSU Technologies. Dr. Mathew has obtained UCLA Corporate Governance Program Certification.
Scientific, Technical, Quality, Regulatory, or Business questions about how to incorporate CryoStor, HypoThermosol, or other Biopreservation Best Practices into your process? Please contact us at the form below, or email Dr. Mathew at firstname.lastname@example.org